迈克生物：转让山东迈克51%股权

Group 1 - The company plans to transfer 51% equity of its subsidiary Shandong Mike Biological Technology Co., Ltd. for a transaction price of 17.41 million yuan [1] - After the transaction, the company will no longer hold equity in Shandong Mike but will establish an office in Shandong to manage and expand its dealer network in the region [1] - The equity transfer will not have a significant impact on the company's main business operations [1] Group 2 - Shandong Mike's projected revenue for 2023 is 243 million yuan, with a net loss of 11.04 million yuan; for 2024, the projected revenue is 227 million yuan, with a net loss of 1.91 million yuan [1] - The transaction partner, Han Siguang, has over 20 years of experience in the medical device distribution and service industry in Shandong [1]